Postsurgical Therapeutics, Inc. ("Postsurgical") is a pharmaceutical company specializing in developing a sustained and controlled drug delivery system (DDS) using polylactic glycolic acid (PLGA) biodegradable polymer. Postsurgical has recognized that its PLGA-based DDS can provide local efficacy of drug(s) without causing systemic side effects. Postsurgical has applied this advantage to reformulate drugs approved previously by the FDA to create a “repurposed drug” for new indications. Currently Postsurgical has 5 different projects under development.
PLGA Microspheres: PLGAs are a family of FDA and European Medicine Agency approved biodegradable polymers that are generally recognized as safe. They are highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins, and various other macromolecules such as DNA, RNA, and peptides. Poly(lactic-co-glycolic acid) (PLGA) is the most widely used biomaterial for microencapsulation and prolonged delivery of therapeutic drugs, proteins, and antigens. The physicochemical properties of PLGA may be varied systematically by changing the ratio of lactic acid to glycolic acid or molecular weight. This in turn alters the release rate of microencapsulated therapeutic molecules from PLGA microparticle formulations.
Postsurgical is a semi-virtual company working with a number of outside collaborators and advisors.
Founder
C.F.O.
Advisor
Mr. Hahn has founded six start-ups: Novatrix, Inc. in 1993, Biocept, Inc. in 1997, Avicule, Inc. in 2004, JCSS Biomedical in 2005, Curexo USA in 2006 and Postsurgical Therapeutics in 2014. He served as Chief Technical Officer and/or Chief Executive Officer and organized each of these companies. These companies raised a total of over $300 million through private investors and venture capital firms. He obtained proprietary technologies by internal technology/product development or through license agreements. His technical expertiseincludes drug delivery system/drug development and cancer diagnostics. In 2006, he sold the assets of three of these companies (Novatrix, Avicule and JCSS) to Curexo, Inc. and in 2019 three projects to Upex-Med. Biocept (liquid biopsy company) became a public company in 2014 (“BIOC”). Mr. Hahn has extensive experiences in M & A and licensing agreements. He received his Ph.D. in organic chemistry from the Ohio State University in 1985 and performed postdoctoral research at Stanford University with Professor Carl Djerassi in 1986. He has 14 issued US patents and 8 pending patent applications.
Mr. Lee has been a seasoned and experienced corporate executive over 20 years with combined expertise in financial accounting, administrative, operations, risk management and strategic planning. He took CFO position at Novatrix, Inc., Avicule, Inc. and JCSS Biomedical, Inc. in 2006 until their successful closings.
He currently acts as CFO at Postsurgical Therapeutics, Inc. since 2014. His main responsibilities are focused on administrative, accounting and finance functions. His previous job experience was with banking industry and he held various executive positions.
He holds BA and Master degrees from Seoul National University and MBA degree from Anderson School, UCLA.
Rey Magaña, is a serial entrepreneur with over 25 years of experience in preclinical and clinical R&D operations, business development, and marketing. He has worked in the pharmaceutical, biotechnology, medical device, and nutritional industries. He has managed projects and R&D programs in cancer, diabetes, cardiovascular, and other therapeutic areas.
He was co-inventor and was part of the team that pioneered Extracellular vesicle and Exosome nucleic acid technologies for applications in molecular diagnostics, drug delivery, and therapeutics. He cofounded Proxy Life Science Holdings a biotechnology company organized to develop those technologies and held the positions of Vice President and Director of Business Development.
He also cofounded Perry Scientific a contract research organization specializing in pre-clinical research services supporting early-stage pharmaceutical, biopharmaceutical, and medical device companies. The company catered to both emerging and established blue-chip companies. Mr. Magana was responsible for strategy, business development, and operations. He held the title of VP and Chief Operations Officer. His key duty was the development and delivery of custom research services including efficacy, pharmacokinetics, and safety studies in areas as diverse as oncology, metabolic diseases, cardiology, dermatology, immunology, drug delivery, cosmetics, nutraceuticals, and medical devices.
He co-founded NutraClinical Inc. a near-shore clinical research organization delivering clinical trial services for the nutritional industry. His primary role was in business development and contract negotiations.
Upex-Med
is a biomedical company based in South Korea and has expertise in developing PLGA microspheres. Their development team has experiences in commercializing several PLGA microsphere products in Korea. Upex-Med uses equipment with a SPG (Shirasu Porous Glass) membrane manufactured by MCTech to prepare PLGA microspheres. It produces a relatively uniform size of microspheres with a superior quality control.
Applied Medical Concepts
is an engineering contract research organization based in China, specializing in developing a catheter-based drug delivery system. Currently it is developing a prototype catheter delivery device for delivering powder formulations into the brain.
Myer, Inc.
is an animal testing facility based in Napa, California. Its founder has over 25 years of experience in pre-clinical and safety studies. Currently, it is performing various animal tests for Postsurgical.
Postsurgical is seeking collaborations and partnerships with pharmaceutical companies interested in repurposed drugs or drug delivery platforms.
Contact usPostsurgical Therapeutics, Inc. is a biopharmaceutical company based in Costa Mesa, CA. Postsurgical is focused on the development of a novel drug delivery platform for the treatment of various diseases including cancer.
